Aligos Therapeutics annual net debt
2019
2020
2021
2022
2023
2024
2025
Aligos Therapeutics Net Debt Growth & History (ALGS)
Aligos Therapeutics's net debt was −$13.1M for fiscal 2025.
View full Aligos Therapeutics company overviewAligos Therapeutics annual net debt history
| Fiscal year | Period ended | Net debt | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$13.1M | $15.6M | — |
| 2024 | 2024-12-31 | −$28.6M | $95.9M | — |
| 2023 | 2023-12-31 | −$124.6M | −$55.8M | — |
| 2022 | 2022-12-31 | −$68.8M | $103.6M | — |
| 2021 | 2021-12-31 | −$172.4M | $35.0M | — |
| 2020 | 2020-12-31 | −$207.4M | −$152.1M | — |
| 2019 | 2019-12-31 | −$55.2M | — | — |
Aligos Therapeutics quarterly net debt
Q4.19
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Net debt | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$26.9M | −$15.1M | — |
| Q1 2026 | 2026-03-31 | −$25.6M | $40.3M | — |
| Q4 2025 | 2025-12-31 | −$13.1M | $15.6M | — |
| Q3 2025 | 2025-09-30 | −$35.9M | −$9.7M | — |
| Q2 2025 | 2025-06-30 | −$11.8M | $23.5M | — |
| Q1 2025 | 2025-03-31 | −$65.9M | −$52.2M | — |
| Q4 2024 | 2024-12-31 | −$28.6M | $95.9M | — |
| Q3 2024 | 2024-09-30 | −$26.2M | $32.5M | — |
| Q2 2024 | 2024-06-30 | −$35.2M | $43.2M | — |
| Q1 2024 | 2024-03-31 | −$13.7M | $53.0M | — |
| Q4 2023 | 2023-12-31 | −$124.6M | −$55.8M | — |
| Q3 2023 | 2023-09-30 | −$58.7M | $14.8M | — |
| Q2 2023 | 2023-06-30 | −$78.4M | −$20.7M | — |
| Q1 2023 | 2023-03-31 | −$66.7M | $23.5M | — |
| Q4 2022 | 2022-12-31 | −$68.8M | $103.6M | — |
| Q3 2022 | 2022-09-30 | −$73.4M | $153.9M | — |
| Q2 2022 | 2022-06-30 | −$57.7M | $117.4M | — |
| Q1 2022 | 2022-03-31 | −$90.2M | $97.3M | — |
| Q4 2021 | 2021-12-31 | −$172.4M | $35.0M | — |
| Q3 2021 | 2021-09-30 | −$227.3M | −$208.8M | — |
| Q2 2021 | 2021-06-30 | −$175.1M | — | — |
| Q1 2021 | 2021-03-31 | −$187.5M | — | — |
| Q4 2020 | 2020-12-31 | −$207.4M | −$152.1M | — |
| Q3 2020 | 2020-09-30 | −$18.5M | — | — |
| Q4 2019 | 2019-12-31 | −$55.2M | — | — |
Aligos Therapeutics net debt trends
Over the last five fiscal years, Aligos Therapeutics's net debt increased from −$207.4M to −$13.1M, a change of $194.3M. The latest reported quarter, Q2 2026, shows −$26.9M.
About the metric
What net debt means
Net debt compares a company’s interest-bearing debt with its cash and cash equivalents. Positive net debt means debt exceeds cash, while a negative value indicates the company has more cash than debt on this measure.
Calculation and source
How net debt is calculated
TickerStat calculates net debt as total interest-bearing debt minus cash and cash equivalents at the same reporting-period end. Short-term investments are not subtracted because they are not included in the standardized cash series. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Aligos Therapeutics source filings ↗